Morgan Stanley Maintains Equal-Weight on Neurocrine Biosciences, Lowers Price Target to $182

Benzinga Newsdesk www.benzinga.com Negative 51.0%

Neg 51% Neu 0% Pos 0%

Morgan Stanley analyst Jeffrey Hung maintains Neurocrine Biosciences (NASDAQ:NBIX) with a Equal-Weight and lowers the price target from $196 to $182.